A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control.

The Journal of Clinical Hypertension
Barry L CarterArthur J Hartz

Abstract

This was a prospective, cluster randomized controlled trial in patients with uncontrolled hypertension aged 21 to 85 years (mean, 61 years). Pharmacists made recommendations to physicians for patients in the intervention clinics (n=101) but not patients in the control clinics (n=78). The mean adjusted difference in systolic blood pressure (BP) between the control and intervention groups was 8.7 mm Hg (95% confidence interval [CI], 4.4-12.9), while the difference in diastolic BP was 5.4 mm Hg (CI, 2.8-8.0) at 9 months. The 24-hour BP levels showed similar effects, with a mean systolic BP level that was 8.8 mm Hg lower (CI, 5.0-12.6) and a mean diastolic BP level that was 4.6 mm Hg (CI, 2.4-6.8) lower in the intervention group. BP was controlled in 89.1% of patients in the intervention group and 52.9% in the control group (adjusted odds ratio, 8.9; CI, 3.8-20.7; P<.001). Physician/pharmacist collaboration achieved significantly better mean BP values and overall BP control rates, primarily by intensification of medication therapy and improving patient adherence.

Associated Clinical Trials

Citations

Oct 28, 2009·Archives of Internal Medicine·Barry L CarterPaul A James
Nov 26, 2009·Archives of Internal Medicine·Barry L CarterYinghui Xu
Oct 13, 2010·Archives of Internal Medicine·Cynthia A WeberBarry L Carter
Nov 23, 2010·Advances in Health Sciences Education : Theory and Practice·Ruth M Gallagher, Helen C Gallagher
Aug 22, 2007·Pharmacy World & Science : PWS·Shannon J Von MuensterYinghui Xu
Mar 3, 2011·International Journal of Clinical Pharmacy·Manuel MorgadoMiguel Castelo-Branco
Apr 30, 2013·Current Hypertension Reports·Leah L ZulligHayden B Bosworth
Jul 22, 2010·Circulation. Cardiovascular Quality and Outcomes·Barry L CarterUNKNOWN Collaboration Among Pharmacists Physicians To Improve Outcomes Now (CAPTION) Trial Investigators
Mar 26, 2011·American Journal of Pharmaceutical Education·Seena L HainesUNKNOWN Professional Affairs Committee
Dec 16, 2011·American Journal of Pharmaceutical Education·Lon J Van WinkleMohammadreza Hojat
Nov 20, 2013·American Journal of Pharmaceutical Education·David S FikeEric J MacLaughlin
Jun 17, 2014·American Journal of Preventive Medicine·Krista K ProiaUNKNOWN Community Preventive Services Task Force
Oct 29, 2013·Research in Social & Administrative Pharmacy : RSAP·Edwin C K TanJohnson George
Oct 23, 2013·Research in Social & Administrative Pharmacy : RSAP·Ainslie M HamerEmily Roberts
Jul 24, 2014·International Journal of Clinical Pharmacy·Lucas Miyake OkumuraCassyano Januário Correr
Aug 28, 2010·Journal of Interprofessional Care·Mohammadreza Hojat, Joseph S Gonnella
Feb 8, 2016·Journal of the American Society of Hypertension : JASH·Steven M SmithBarry L Carter
Jun 20, 2015·Research in Social & Administrative Pharmacy : RSAP·Ulla HedegaardLene Juel Kjeldsen
May 11, 2011·Journal of the American Pharmacists Association : JAPhA·Jeanine P Abrons, Marie Smith
Oct 2, 2012·Journal of the American Pharmacists Association : JAPhA·Grace L Earl, Jule Anne Henstenburg
Sep 14, 2013·Journal of the American Pharmacists Association : JAPhA·Candis M MorelloKelly C Lee
Mar 20, 2013·Research in Social & Administrative Pharmacy : RSAP·David E DemikBarry L Carter
Dec 31, 2015·International Journal of Clinical Pharmacy·Tyler GumsEric Foster
Apr 20, 2010·Journal of the American Society of Hypertension : JASH·Alan H GradmanMichael A Weber
May 9, 2015·Contemporary Clinical Trials·Barry L CarterLinnea A Polgreen
Mar 7, 2015·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Daisuke SonMiho Utsumi
Jun 14, 2008·The Journal of Clinical Hypertension·Michael E ErnstGeorge R Bergus
Aug 30, 2008·Pharmacotherapy·Cynthia A WeberYinghui Xu
Jun 26, 2008·Pharmacotherapy·Jessica L MilchakUNKNOWN Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Feb 19, 2009·The Journal of Clinical Hypertension·Barry L Carter
Sep 8, 2012·The International Journal of Pharmacy Practice·Derjung M TarnBetty A Chewning
Mar 4, 2011·The Journal of Clinical Hypertension·Alan H GradmanUNKNOWN American Society of Hypertension Writing Group
Jan 13, 2012·The Journal of Clinical Hypertension·Barry L CarterBeverly B Green
Apr 26, 2013·The Journal of Clinical Hypertension·Ziqian ChenBarry L Carter
Jun 9, 2011·The Journal of Clinical Hypertension·Danielle M WentzlaffLucinda M Buys
Jun 5, 2013·The Journal of Clinical Hypertension·Barry L CarterUNKNOWN Collaboration Among Pharmacists and Physicians to Improve Outcomes Now (CAPTION) trial investigators

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Circulation. Cardiovascular Quality and Outcomes
Barry L CarterCollaboration Among Pharmacists Physicians To Improve Outcomes Now (CAPTION) Trial Investigators
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Alan J ZillichClarence D Kreiter
© 2022 Meta ULC. All rights reserved